The abstract is read at the publisher; the summary is JClub's.
For advanced biliary tract cancer, ASCO’s 2026.1.0 living guideline recommends broad tissue DNA/RNA NGS at diagnosis and reserves plasma liquid biopsy mainly for when tissue is unavailable.
- Why it matters: Treatment selection and biomarker matching in advanced BTC depend on reliable detection of targetable alterations, but access to tissue can be limited and evidence evolves over time.
- What they did: An ASCO Expert Panel performed a systematic review, using six studies on liquid–tissue concordance, nine RCTs for first-line therapy, and phase III/II RCTs plus biomarker-focused single studies to shape recommendations.
- The result: First-line pMMR/MSS advanced BTC is recommended for immune checkpoint inhibitors plus chemotherapy, dMMR/MSI-H supports pembrolizumab monotherapy, and second-line options are specified for multiple biomarker-defined subgroups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.